Article

Development of a SARS-CoV-2 total antibody assay and the dynamics of antibody response over time in hospitalized and non-hospitalized patients with COVID-19

2020-06-19

Abstract excerpt

SARS-CoV-2 infections often cause only mild disease that may evoke relatively low antibody titers compared to patients admitted to hospitals. Generally, total antibody bridging assays combine good sensitivity with high selectivity. Therefore, we developed sensitive total antibody bridging assays for detection of SARS-CoV-2 antibodies to the receptor-binding domain (RBD) and nucleocapsid protein (NP), in addition t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 19112d08-c83d-5e1c-9444-21f80a142aef
DOI: 10.1101/2020.06.17.20133793

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development of a SARS-CoV-2 total antibody assay and the dynamics of antibody response over time in hospitalized and non-hospitalized patients with COVID-19DOI 10.1101/2020.06.17.20133793Read

SARS-CoV-2 antibody responses determine disease severity in COVID-19 infected individualsSemantic proximity Read

Rapid generation of neutralizing antibody responses in COVID-19 patientsSemantic proximity Read

Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody featuresSemantic proximity Read

Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severitySemantic proximity Read

Vaccination of COVID-19 Convalescent Plasma Donors Increases Binding and Neutralizing Antibodies Against SARS-CoV-2 VariantsSemantic proximity Read

Towards Internationally standardised humoral Immune Correlates of Protection from SARS-CoV-2 infection and COVID-19 diseaseSemantic proximity Read

Quantifying post-vaccination protective anti-SARS-CoV-2 IgG antibodies in blood and saliva with a fully automated, high throughput digital immunoassaySemantic proximity Read

Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variantsSemantic proximity Read

Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralizationSemantic proximity Read

Clinical and laboratory considerations: Determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19Semantic proximity Read

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor populationSemantic proximity Read

The Dynamic Changes of Antibodies against SARS-CoV-2 during the Infection and Recovery of COVID-19Semantic proximity Read